Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Stopped early · Phase 1/Phase 2

Conditions studied: Non Hodgkin Lymphoma

In brief

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

Key facts

Study ID

NCT06088654

Run by

Innate Pharma

People needed

23

Starts

2024-03-04

Expected to finish

2026-02-06

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States
• Cedars Sinai — Los Angeles, California, United States
• Siteman Cancer Center — St Louis, Missouri, United States
• Icahn School Of Medicine At Mount Sinai — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Wollongong Private Hospital — Wollongong, New South Wales, Australia
• Monash Health — Clayton, Victoria, Australia
• Peninsula Private Hospital — Frankston, Victoria, Australia
• Austin Health — Heidelberg, Australia
• Institute Bergonie — Bordeaux, France
• Centre Hospitalier Regional Universitaire de Lille — Lille, France
• Hospices Civils de Lyon — Lyon, France
• Hôpital de la Coception — Marseille, France
• Centre Hospitalier Universitaire de Nantes — Nantes, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.